AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05464485 — intervention group
Intervention type: PROCEDURE
Intervention: ACL hamstring reconstructions using semitendinosus (ST) tendon only
Description: ACL reconstruction with a ST tendon graft received a reconstruction according to the Tape Locking Screw technique (FH Industrie, Quimper, France) with a dedicated interference screw
Study NCT05464485 — intervention group
Intervention type: PROCEDURE
Intervention: ACL hamstring reconstructions using semitendinosus and gracilis (ST/G) tendon
Description: ACL reconstruction with a ST/G tendon graft received a reconstruction with the anteromedial portal technique with endobutton fixation (Smith \& Nephew, London, UK).
Study NCT01943539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro-typical controls and ADHD will receive EVO game play.
Description: EVO mobile video application
Study NCT01196910 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: treatment by HLPFC coil
Description: DTMS treatment will be given for 3 weeks, 5 days a week. Before each DTMS treatment, neural network excitation practice will be done using AttenGo software (AttenGo, Herzlia, Israel).~Each treatment day: Follow-up to evaluate clinical side effects of treatment. Two additional meetings with DTMS treatment and follow-up will be held to evaluate the efficacy of treatment and side effects. The first will be four weeks after the end of the daily treatment phase; the second eight weeks after the end of the daily treatment phase.
Study NCT00382473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program - 8 weeks
Description: No drugs. Regular aerobic exercise in structured prescription format
Study NCT01196910 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: treatment by HLPFC coil
Description: DTMS treatment will be given for 3 weeks, 5 days a week. Before each DTMS treatment, neural network excitation practice will be done using AttenGo software (AttenGo, Herzlia, Israel).~Each treatment day: Follow-up to evaluate clinical side effects of treatment. Two additional meetings with DTMS treatment and follow-up will be held to evaluate the efficacy of treatment and side effects. The first will be four weeks after the end of the daily treatment phase; the second eight weeks after the end of the daily treatment phase.
Study NCT03927027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosulfan Blue
Description: Given SC
Study NCT03927027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosulfan Blue
Description: Given SC
Study NCT03927027 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary Lymph Node Dissection
Description: Undergo ALND
Study NCT03927027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Lymph Node Dissection
Description: Undergo ALND
Study NCT03927027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mapping
Description: Undergo ARM
Study NCT04311476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Umbilical Cord Blood Mononuclear Cells infusion Therapy
Description: Evaluate Autologous cord blood cells infusion on prevention of bronchopulmonary dysplasia in very preterm neonates
Study NCT03927027 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02849106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy to obtain a chemogram
Description: All patients enrolled will have biopsies (on primary tumor or on a metastasis) before treatment in order to obtain a chemogram by ex vivo 3D culture cells
Study NCT03927027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03927027 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04311476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodiun Chloride
Description: 0.9% Sodiun Chloride in control group
Study NCT02468089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbepenem
Study NCT02468089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbepenem
Study NCT03927027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03522246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Oral rucaparib will be administered twice daily
Study NCT03522246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV nivolumab will be administered once every 4 weeks
Study NCT03522246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo tablets will be administered twice daily
Study NCT03522246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablets will be administered twice daily
Study NCT03522246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV Infusion
Description: IV placebo will be administered once every 4 weeks
Study NCT03522246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV Infusion
Description: IV placebo will be administered once every 4 weeks
Study NCT02468089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Study NCT02468089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin
Study NCT02468089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMCSF (of Granulocyte-Monocyte Colony-Stimulating Factor) .
Study NCT01738139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO
Study NCT01738139 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03760640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC
Study NCT03760640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study NCT06627634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastatectomia and standard treatment for resectable disease.
Description: Rather than palliative chemotherapy, the intervention offered to participants is preoperative chemotherapy, resection of primary tumour and metastatectomia of oligometastatic spread to the liver. If fit for post-operative chemotherapy, this is offered as well.
Study NCT02258035 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Sampling of 100-150 ml of blood
Study NCT04384224 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: use disposable sterile steel needles to insert to the acupuncture point
Study NCT04384224 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: acupuncture
Description: use disposable sterile steel needles to insert to the acupuncture point
Study NCT04384224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: use disposable sterile steel needles to insert to the acupuncture point
Study NCT03762954 — intervention group
Intervention type: OTHER
Intervention: Neurocognitive function assessment
Description: Neurocognitive function will be assessed via a phone battery derived from standard cognitive tests proven feasible and valid to assess memory, attention, reasoning, and executive functioning. Functional status will also be assessed via phone. The duration of time required for the patient to complete telephone interview for neurocognitive and functional assessment will be approximately 45 minutes per time point.
Study NCT02471807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards FORMA Tricuspid Transcatheter Repair System
Study NCT02726841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open thoracoabdominal aortic repair + abdominal stenting
Description: Thoracoabdominal aortic dissection (TAAD) repair + bare aortic stent (Djumbodis) implantation
Study NCT02726841 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic thoracoabdominal aortic repair
Description: Thoracoabdominal aortic dissection (TAAD) repair
Study NCT04121533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplement for vitamin D (cholecalciferol), glucosamine sulfate, and omega-3 fatty acids. Supplement was taken orally every day for 84-days.
Study NCT04121533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol)
Description: Vitamin D (cholecalciferol). Supplement was taken orally every day for 84-days.
Study NCT04121533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate and omega-3 fatty acids
Description: Glucosamine sulfate and omega-3 fatty acids supplement was taken orally every day for 84-days.
Study NCT00685334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Participants will take olanzapine daily for 12 weeks.
Study NCT00685334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Participants will take aripiprazole daily for 12 weeks.
Study NCT04468282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VGB-ST
Description: Single oral administration of 500 mg VGB-ST
Study NCT04468282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGB-ST
Description: Single oral administration of 500 mg VGB-ST
Study NCT00158925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EASYTRAK EPI lead
Description: EASYTRAK EPI lead
Study NCT02934334 — intervention group
Intervention type: OTHER
Intervention: Observational
Study NCT00529191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Pill, initially at 10 mg, then after 4 weeks, 20 mg Once daily for a total of 12 months
Study NCT00619541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusional 5-Fluorouracil
Description: 5-FU 3000 mg/sqm 48 hours continuous infusion every 14 days. 5-FU will be administered for a maximum of 12 cycles.
Study NCT00619541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Bay 43-9006)
Description: Sorafenib 400 mg bid orally continuously. Sorafenib will be administered from the start of treatment in combination with 5-FU until progression of disease.
Study NCT02500030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glossopharyngeal Breathing
Description: Glossopharyngeal Breathing is a type of lung recruitment technique where the patients take a multiple inssuflations with their glossopharyngeal muscle.
Study NCT02500030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air Stacking
Description: Air Stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a manual resuscitator.
Study NCT04180410 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EIT
Description: Electrical Impedance Tomography is performed before extubation, during follow-up visits of extubation and 48H after extubation. Follow-up visits are shortened in case of extubation failure.
Study NCT00577330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Myalgesin™ (celery seed extract, Boswellia serrata extract, Phellodendron extract)
Description: Twice daily
Study NCT00577330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myalgesin™ (celery seed extract, Boswellia serrata extract, Phellodendron extract)
Description: Twice daily
Study NCT03538392 — intervention group
Intervention type: DEVICE
Intervention: Serranator® Alto
Description: Serranator® Alto PTA Serration Balloon Catheter
Study NCT04467541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Enterovirus Type 71 (EV71) Vaccine (Vero Cell)
Description: Inactivated Enterovirus Type 71 (EV71) Vaccine safety in healthy adults followed by safety and immunogenicity administered in two consecutive doses, one-month apart among children aged 6 to 71 months
Study NCT02162745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic solution (NaCl 0.9%)
Study NCT02162745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic solution (NaCl 3%)
Study NCT03845998 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: use the three-finger method
Description: The size of the laryngeal mask airway was determined by choosing the laryngeal mask that best matched the combined widths of the patient's index, middle and ring fingers.
Study NCT03845998 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: use the weight-related method
Description: The size of the laryngeal mask airway was determined by the patient's weight.
Study NCT00991172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN475
Description: Single Subcutaneous injection dose level 1
Study NCT03623412 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 75g oral glucose tolerance test
Description: Women with one abnormal value in the OGTT during pregnancy (minor degree of glucose intolerance) will be offered a post-partum 75g GTT (Glucose Tolerance Test), similar to that offered to women with GDM
Study NCT03623412 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 75g GTT
Description: post-partum GTT
Study NCT00991172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN475
Description: Single subcutaneous injection dose level 2
Study NCT00991172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: Placebo Subcutaneous injection
Study NCT01205243 — intervention group
Intervention type: DRUG
Intervention: ZIAGEN®
Description: Basically there is no treatment allocation. Subjects who would be administrated ZIAGEN® at their physician's discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Study NCT03188211 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: E-learning educational program
Description: A number of 10 cases of patients 65 years of age or older with AF, acutely admitted to Internal Medicine or Geriatric wards for any medical condition, will be edited into the Dr. Sim system. Diagnostic and therapeutic choices for ordinary and/or complex medical situations will be taken through the development of the simulated scenario.
Study NCT03188211 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Any educational program will be delivered to clinicians assigned to control arm
Study NCT02399878 — intervention group
Intervention type: DRUG
Intervention: Inspiratory oxygen
Study NCT03631667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-benzo[a]pyrene
Description: Oral micro-dose (50 ng) (5.4 nCi)
Study NCT03631667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-benzo[a]pyrene plus phenanthrene
Description: Oral micro-dose of 50 ng (5.4 nCi) \[14C\]-benzo\[a\]pyrene plus 1250 ng phenanthrene
Study NCT05295160 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: weight loss by very low energy diet intake which may differ in protein or carbohydrate content
Description: The anthropometric, endocrine and metabolic status is tested before, after 7 days and after 15 kg weight loss
Study NCT02392208 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Telavancin
Description: A single 5 mg/kg dose of telavancin is administered intravenously (IV).
Study NCT02392208 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pharmacokinetic Blood Sampling
Description: Blood samples are collected to assess telavancin plasma concentrations.
Study NCT03386058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporary device deactivation
Description: Patient-controlled, temporary deactivation of implanted device
Study NCT02778880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study NCT02778880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study NCT03378219 — intervention group
Intervention type: DRUG
Intervention: Sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form:injection Route of administration: subcutaneous
Study NCT03645252 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vein interruption before any other surgical manipulation
Description: The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).~In the vein first group, the lobar vein is dissected and the cartridge and anvil of a vascular cartridge stapler are placed on either side of the vein. The vein is punctured above the stapler with a 23-gauge needle and 7.5 ml of blood is drawn. Finally, the vein is cut. The intervention then proceeds in the usual manner.
Study NCT03645252 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arteries interruption before vein interruption
Description: The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).~In the arteries before vein group, lobar arteries are first dissected and interrupted (+/- the bronchus and inter-lobar fissures). The lobar vein is then dissected and blood sample is performed as described above.
Study NCT01277289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 500 mg/20 ml encapsulated in erythrocytes, every month for 12 months
Study NCT01277289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: 500 mg/20 ml encapsulated in erythrocytes, every month for 12 months
Study NCT02169635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: macular buckle
Description: macular buckle with a three-armed silicone capsule
Study NCT00537940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: 150, 300, 450 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
Study NCT00537940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: 300, 600, 1200, 2000 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
Study NCT02591407 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block
Description: This is a one time injection of Exparel in the plane between the internal oblique and transversus abdominis muscles
Study NCT01369719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osveral
Description: receive 20 mg/kg daily orally
Study NCT01369719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desferal
Description: 40-50mg/Kg for 6 nights in each week subcutaneously
Study NCT05868642 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subarachnoid block
Description: subarachnoid block with levobupivacaine at different dosage for pation undergoing total hip arthroplasty
Study NCT05868642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subarachnoid block
Description: subarachnoid block with levobupivacaine at different dosage for pation undergoing total hip arthroplasty
Study NCT01257126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac potassium
Study NCT01257126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nimesulide
Study NCT02591407 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Epidural Analgesia
Description: Epidural catheter placed prior to the operation in the standard fashion
Study NCT04144881 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: coronary computed tomography
Description: patients randomized in this arm will perform computed coronary tomography 6 months after the index percutaneous revascularization on unprotected left main artery
Study NCT04552119 — intervention group
Intervention type: DEVICE
Intervention: HEALICOIL Knotless PEEK
Description: HEALICOIL Knotless PEEK Self-Tapping HEALICOIL Knotless Non-Self Tapping
Study NCT04552119 — intervention group
Intervention type: DEVICE
Intervention: HEALICOIL Knotless REGENESORB
Description: HEALICOIL Knotless REGENESORB Self -Tapping HEALICOIL Knotless REGENSORB Non-Self Tapping
Study NCT04156100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN1223
Description: AGEN1223 is a bispecific antibody.
Study NCT04156100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN1223 and balstilimab
Description: AGEN1223 is a bispecific antibody and balstilimab an anti-PD-1 Monoclonal Antibody.
Study NCT00063362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over three weeks to a minimum blood level of 0.5 milliequivalent /L (mEq/L).
Study NCT00063362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lithium
Description: Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over three weeks to a minimum blood level of 0.5 milliequivalent /L (mEq/L).